White Paper

Whitepaper : Dr.Reddy's 2 DG- A promising treatment in hospitalized COVID-19 patients

2-Deoxy-D-Glucose (2-DG) is an anti-viral and anti-inflammatory drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS) of Defense Research and the Development Organization (DRDO). Dr. Reddy's collaborated with DRDO to conduct clinical trials for 2-DG in COVID-19 patients. Based on phase II and the phase III studies in India, 2-DG has received an emergency use authorization as an adjunct therapy in moderate to severe COVID-19 patients in the hospital setting.

Dr. Reddy's is the first firm to successfully provide access to 2-DG for COVID-19 patients. As a result, we are able to offer our customers early access to the API and finished formulation for specific markets. Want to know more ? please fill in the contact details to read the whitepaper on our 2 DG API and finished product offerings.

Explore other Whitepapers:

Know More

Email us: api@drreddys.com
+91 40 49002222

Download Now

Please fill the Contact form below in order to view the white paper

* I agree and accept the Privacy Policy and Terms of Use of this website.

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Let’s talk API sourcing live at

Tackle sourcing bottlenecks and compliance hurdles

Hall E1 Booth H28 24-26 June 2025, Shanghai

Book a Meeting